Dr. Chiaravallotti Adele
Medical activity: Works in IRCCS Fondazione G.B. Bietti in Via Livenza, 3 and in Via di santo Stefano Rotondo 6, at Presidio Ospedaliero Britannico, Roma
Scientific publication : PubMed
- October 26th, 1999 – Degree in Medicine and Surgery. University of Rome “La Sapienza”. Vote 110/110 cum laude.
- May 2000 – Qualification diploma for the profession of Doctor-Surgeon. University of Rome “La Sapienza”.
- October 30, 2003 – Specialization in Ophthalmology. University of Rome “La Sapienza”. Vote 70/70 with honors.
- April 2001- Matriculation on the register of the Medical Order of Rome.
• From January 2018. Medical Director with permanent contract with the G.B.Bietti I.R.C.C.S. Foundation for the study and research in Ophthalmology with assistance activities at the Center for Maculopathies of the “San Giovanni-Addolorata Hospital.
• From 2016 January 1st to December 2017. Coordinated and ongoing Collaboration Agreement at the G.B.Bietti I.R.C.C.S. Foundation for the study and research in Ophthalmology with assistance activities at the Center for Maculopathies of the “San Giovanni-Addolorata Hospital.
• From 2015 January 1st Project work contract with the G.B.Bietti I.R.C.C.S. Foundation for the study and research in Ophthalmology.
• From 2008 June 1st to 2014 December 31st: 1) Project work contract at the G.B.Bietti I.R.C.C.S. Foundation for the study and research in Ophthalmology. 2) Coordinated and ongoing collaboration agreement at the Center for Maculopathies of the “San Giovanni-Addolorata Hospital “
• From January 2006 to December 2007. Research scholarship for carrying out clinical and research activities in the field of the medical retina announced by the G.B.Bietti I.R.C.C.S. Foundation for the study and research in Ophthalmology (Retina Medica Department directed by Dr. M. Varano) where he deals with diagnostics using retinal fluorescence angiography, angiography with indocyanine green, microperimetry with SLO and with MP1 and therapy of chorioretinal pathologies and macular by laser, photodynamic therapy, intravitreal injections of anti-VEGF drugs.
• From January 2004 to December 2005. Research scholarship for carrying out clinical-surgical and research activities in the field of vitreo-retinal pathology announced by the G.B.Bietti I.R.C.C.S. Foundation for the study and research in Ophthalmology.
AIMO
• Functional and morphological retinal changes in diabetic macular edema treated with Pegaptanib
• 12-month open-label study to evaluate the safety and efficacy of intravitreal ranibizumab administered in conjunction with photodynamic therapy with Visudyne® (PDT) in naïve patients with subfoveal choroidal neovascularisation secondary to age-related macular degeneration.
• 6-month, phase 3, multi-center, masked, randomized, placebo-controlled study (with 6-month open label extension) to evaluate the safety and efficacy of 700 µg and 350 µg slow-release dexametazone (DEX PS DDS) in the treatment of patients with macular edema following central retinal vein occlusion or branch occlusion.
• MONTBLANC Study. A 12-month randomized, double-masked, multicenter, phase II study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with LucentisTM versus LucentisTM monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
• VIEW2 Study. A randomized, double masked, active controlled, phase 3 study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF Trap-Eye in subjects with neovascular age-related macular degeneration (AMD).
• DEGAS Study. A phase II prospective, randomized, multi-center, diabetic macular edema dose ranging, comparator study evaluating the efficacy and safety of PF-04523655 versus laser therapy (DEGAS).
• GALILEO Study. A randomized, double-masked, sham-controlled phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal administration of VEGF Trap-Eye in subjects with macular edema secondary to central retinal vein occlusion (CRVO).
• MIZAR Study. A clinical safety and efficacy comparison of NEVANAC® 0.1% to Vehicle following cataract surgery in diabetic retinopathy patients.
• A 12 month, phase III, randomized, double-masked, multicenter, active-controlled study to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab vs verteporfin PDT in patients with visual impairment due to choroidal neovascularisation secondary to pathologic myopia.
• RETAIN Study. A 2 year randomized, single-masked, multicenter, controlled phase IIIb trial assessing the efficacy and safety of 0.5 mg ranibizumab in two “treat and extend” treatment algorithms vs 0.5 mg ranibizumab as needed in patients with macular edema and visual impairment secondary to diabetes mellitus.
• COMO Study. A 12-month, multicentre, randomized, parallel group study to compare the efficacy and safety of Ozurdex® versus Lucentis® in patients with branch retinal vein occlusion.
• VIVID DME Study. A randomized, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macula edema.
• A Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of 700 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in Patients with Diabetic Macular Edema.
• A phase 3 randomized, double-masked, controlled trial to estblish the safety and efficacy of intravitreous administration of Fovista (Anti PDGF-B pegylated aptamer) administered in combination with Lucentis compared to Lucentis monotherapy in subjects with subfoveal neovascular age-related macular degeneration . (Fovista-OPH1002)
• A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial qrowth factor (VEGF) driven choroidal neovascularization ( CNV) .MINERVA
• An open label randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular age-related macular de generation ( nAMD) AZURE
• Managing neovascular age-related macular degeneration (nAMD) over 2 years with a Treat and Extend (T&E) regimen of 2 mg intravitreal (IVT) aflibercept – a randomized, open-label, active-controlled, parallel-group phase IV / IIIb study (ARIES)
• A multi-center, single arm, interventional Phase 4 study to evaluate a Treat and Extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion CENTERA
• Safety and efficacy of Abicipar Pegol in patients with neovascular Age-related Macular Degeneration.
• A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy (Fovista-OPH1004)
• Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients
With Neovascular Age-related Macular Degeneration
(SEQUOIA)
• One year, single arm, open label, multicenter, phase IV study using multimodal imaging to guide disease activity assessment through innovative early predictive anatomical biomarkers of fluid resolution in wAMD patients treated with brolucizumab – IMAGINE study
• A phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of faricimab in patients with macular edema secondary to central retinal or hemiretinal vein occlusion. COMINO study
• A phase 3, multicenter, double-masked, randomized study to evaluate the efficacy and safety of intravitreal OPT-302 in combination with aflibercept, compared with aflibercept alone, in participants with neovascular Age – related Macular Degeneration. COAST study
• Randomized, double-masked, active-controlled, phase 3 study of efficacy and safety of high dose aflibercept in patients with Neovascular Age-Related Macular Degeneration.
- CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Early and Late Morphological and Functional Changes After Verteporfin Photodynamic Therapy. Iacono P, Tedeschi M, Boccassini B, Chiaravalloti A, Varano M, Parravano M. Retina. 2018 Jan 16. doi: 10.1097/IAE.0000000000002040. [Epub ahead of print]
- FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION. Iacono P, Battaglia Parodi M, Selvi F, Parravano MC, Chiaravalloti A, Varano M, Bandello F. Retina. 2017 Oct;37(10):1931-1941. doi: 10.1097/IAE.0000000000001436.
- Exploring the morphological and functional retinal changes after dexamethasone intravitreal implant (Ozurdex®) in macular edema due to retinal vein occlusion. Parravano M, Oddone F, Boccassini B, Giorno P, Chiaravalloti A, Tedeschi M, Scarinci F, Varano M. Ophthalmic Res. 2014;51(3):153-60. doi: 10.1159/000357275. Epub 2014 Mar 13.
- Photodynamic therapy in subfoveal and juxtafoveal myopic choroidal neovascularization: a 10-year retrospective analysis. Varano M, Iacono P, Giorno P, Chiaravalloti A, Parravano M.
Ophthalmologica. 2014;231(4):204-10. doi: 10.1159/000357504. Epub 2014 Jan 25. - Single-session photodynamic therapy combined with intravitreal ranibizumab for neovascular age-related macular degeneration: a comprehensive functional retinal assessment.
Parravano M, Parisi V, Ziccardi L, Chiaravalloti A, Tedeschi M, Cacciamani A, Boccassini B, Boninfante A, Varano M.
Doc Ophthalmol. 2013 Dec;127(3):217-25. doi: 10.1007/s10633-013-9404-z. Epub 2013 Aug 13. - Functional and structural assessment of lamellar macular holes. Parravano M, Oddone F, Boccassini B, Chiaravalloti A, Scarinci F, Sciamanna M, Boninfante A, Tedeschi M, Varano M.
Br J Ophthalmol. 2013 Mar;97(3):291-6. doi: 10.1136/bjophthalmol-2011-301219. Epub 2012 Dec 19. - Foveal microstructure and functional parameters in lamellar macular hole. Reibaldi M, Parravano M, Varano M, Longo A, Avitabile T, Uva MG, Zagari M, Toro M, Boscia F, Boccassini B, Chiaravalloti A, Mariotti C, Reibaldi A. Am J Ophthalmol. 2012 Dec;154(6):974-980.e1. doi: 10.1016/j.ajo.2012.06.008. Epub 2012 Sep 8.
- Reproducibility of macular thickness measurements using Cirrus SD-OCT in neovascular age-related macular degeneration. Parravano M, Oddone F, Boccassini B, Menchini F, Chiaravalloti A, Schiavone M, Varano M. Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4788-91. doi: 10.1167/iovs.09-4976. Epub 2010 Apr 30.
- Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab: 24-month results. Parravano M, Oddone F, Tedeschi M, Chiaravalloti A, Perillo L, Boccassini B, Varano M. Retina. 2010 Jul-Aug; 30 (7): 1017-24. doi: 10.1097 / IAE.0b013e3181cfd3c6.
- Choroidal neovascularization in angioid streaks and pseudoxanthoma elasticum: 1 year follow-up. Schiano Lomoriello D, Parravano MC, Chiaravalloti A, Varano M. Eur J Ophthalmol. 2009 Jan-Feb; 19 (1): 151-3.
- Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab. Parravano M, Oddone F, Tedeschi M, Schiano Lomoriello D, Chiaravalloti A, Ripandelli G, Varano M. Retina. 2009 Mar; 29 (3): 329-34. doi: 10.1097 / IAE.0b013e31819093e6.
- Posterior vitreous detachment and retinal detachment after cataract surgery. Ripandelli G, Coppé AM, Parisi V, Olzi D, Scassa C, Chiaravalloti A, Stirpe M. Ophthalmology. 2007 Apr; 114 (4): 692-7. Epub 2007 Jan 17.
